Evelo Biosciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
Evelo Biosciences, a clinical-stage biotechnology company, announced a conference call on October 28, 2021, at 8:30 a.m. ET to discuss its Q3 2021 financial results and business highlights. The call can be accessed by dialing 866-795-3242 (domestic) or 409-937-8909 (international). Evelo focuses on developing SINTAX™ medicines for inflammatory diseases and cancer, with candidate products EDP1815, EDP1867, EDP2939, and EDP1908 currently in development. For more details, visit evelobio.com.
- Evelo has four product candidates in development targeting inflammatory diseases and cancer.
- Potential for SINTAX™ medicines to offer effective treatments for various health issues.
- None.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing SINTAX™ medicines as a new modality of orally delivered treatments for inflammatory disease, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, October 28, 2021, to report its third quarter 2021 financial results and discuss business highlights.
To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 7574834. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered product candidates that are designed to act on the small intestinal axis, SINTAX™, with systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems. The Company’s first product candidates are pharmaceutical preparations of single strains of microbes selected for their potential to offer defined pharmacological properties. Evelo’s therapies have the potential to be effective, safe, and affordable medicines to improve the lives of people with inflammatory diseases and cancer.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contact
Investors:
Kendra Sweeney, 239-877-7474
ksweeney@evelobio.com
Media:
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
FAQ
What is the date and time for Evelo's Q3 2021 earnings call?
How can I access the live webcast of Evelo's earnings call?
What product candidates is Evelo developing?
What is the focus of Evelo Biosciences?
